Newer Lung Cancer Drug Alone Beats Older Combination Therapy in Real-World Study
A large real-world study in China found that third-generation EGFR inhibitor monotherapy extended progression-free survival in advanced EGFR-mutant lung cancer ...
Tag: osimertinib
Hidden Epigenetic Switches May Let Lung Cancer Cells Survive Treatment and Seed Relapse
A new review argues that epigenetic plasticity in drug-tolerant persister cells, not fixed cancer stem cell identity, may explain relapse ...
Osimertinib Outcomes in EGFR-Mutated Lung Cancer Hinge on Five Prognostic Factors, Meta-Analysis Finds
A new meta-analysis of 4,070 patients identifies EGFR L858R, poor performance status, and brain metastases as high-certency predictors of poorer ...
Lung Cancer That Hid in the Uterus: Rare Metastasis Fooled Doctors
A 77-year-old woman's uterine tumor turned out to be metastatic lung adenocarcinoma, a case highlighting how immunohistochemistry and genomic sequencing ...
Blood Test Reveals How Lung Cancer Outsmarts Osimertinib in Landmark Liquid Biopsy Study
A Thai prospective study used plasma-based 52-gene sequencing to map how T790M-positive lung cancers resist osimertinib, finding heterogeneous resistance mutations ...
PET Scan Glycolysis Measure Predicts Survival in EGFR-Mutant Lung Cancer on Targeted Therapy
A baseline PET/CT scan's SUVmax independently predicts progression-free survival in EGFR-mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Lung Cancer Pills That Target EGFR May Quietly Weaken the Heart, Study Warns
A retrospective Chinese cohort study reports rare but serious cardiovascular toxicity, including heart failure and QTc prolongation, in patients with ...
Hidden Fibroblast Subtype Drives Lung Cancer Growth and Weakens Immunotherapy
A multimodal single-cell and spatial study has uncovered a collagen-producing fibroblast subtype enriched in EGFR-mutant non-small cell lung cancer that ...
Who Needs Intensive Lung Cancer Therapy? New Algorithm Aims to Match EGFR-Mutant Patients to the Right First Treatment
A new review proposes a risk-adapted algorithm to help clinicians decide which patients with advanced EGFR-mutant lung cancer need intensive ...
After Nine Years of ALK Drugs, Lung Cancer Switches Gears—and a Second Mutation Saves the Day
A case report documents an ALK-rearranged lung cancer patient who acquired a druggable EGFR L858R mutation after nearly nine years ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!